Table 1 Patient profiles
Characteristic | Value |
|---|---|
Total number of patients | 31 |
Age (year) | 55.1 ± 15.5 (16.0–81.0) |
Gender (M:F) | 12:19 |
ECOG performance status | |
 0 | 8 (25.8%) |
 1 | 23 (74.2%) |
Primary tumour site | |
 Pancreas | 17 (54.8%) |
 Stomach | 5 (16.1%) |
 Small bowel | 2 (6.5%) |
 Rectum | 4 (12.9%) |
 Unknown | 3 (9.7%) |
Differentiation of tumour | |
 Well-differentiated | 31 (100.0%) |
NET WHO grade | |
 1 | 8 (25.8%) |
 2 | 20 (64.5%) |
 3 | 2 (6.5%) |
 Unknown | 1 (3.2%) |
Median Ki-67 index (%) | 7.5 (0.5–25.0) |
Existence of carcinoid symptoms | 8 (25.8%) |
Previous treatment | |
 Surgery | 14 (45.2%) |
 Chemotherapy | 4 (12.9%) |
Hepatic tumour volume assessed by CT or MRI | |
 0–25% | 15 (48.4%) |
 > 25% | 10 (32.2%) |
 Unknown | 6 (19.4%) |
Best response after lanreotide therapy | |
 Partial response | 1 (3.2%) |
 Stable disease | 28 (90.3%) |
 Progressive disease | 2 (6.5%) |
Progression of disease after lanreotide therapy | 20 (64.5%) |
Median PFS after lanreotide therapy (months) | 14.4 (1.3–34.9) |